A Once-Rejected Antibiotic Equals Standard for Complicated Staph Infections
WASHINGTON — Investigational ceftobiprole was just as effective as daptomycin for bacterial bloodstream infections caused by Staphylococcus aureus bacteremia, the phase III ERADICATE trial demonstrated. In the randomized head-to-head comparison, post-treatment success at 70 days was 69.8% with ceftobiprole and 68.7% with daptomycin, meeting prespecified criteria for non-inferiority, Thomas Holland, MD, of Duke University in […]